{"nctId":"NCT01685242","briefTitle":"A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","startDateStruct":{"date":"2012-09"},"conditions":["Allergic Conjunctivitis"],"count":100,"armGroups":[{"label":"AC-170 0.24%","type":"EXPERIMENTAL","interventionNames":["Drug: AC-170 0.24%"]},{"label":"AC-170 0%","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: AC-170 0%"]}],"interventions":[{"name":"AC-170 0.24%","otherNames":[]},{"name":"AC-170 0%","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* positive bilateral conjunctival allergen challenge (CAC)reaction\n\nExclusion Criteria:\n\n* known contraindications or sensitivities to the study medication or its components\n* any ocular condition that, in the opinion of the investigator, could affect the subjects safety trial parameters\n* use of disallowed medication during the period indicated prior to the enrollment or during the study","healthyVolunteers":false,"sex":"ALL","minimumAge":"10 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Ocular Itching at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.76","spread":"0.940"},{"groupId":"OG001","value":"2.69","spread":"0.663"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.85","spread":"0.938"},{"groupId":"OG001","value":"2.74","spread":"0.824"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":"0.971"},{"groupId":"OG001","value":"2.53","spread":"1.058"}]}]}]},{"type":"PRIMARY","title":"Ocular Itching at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ocular itching was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ocular itching score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.00","spread":"0.911"},{"groupId":"OG001","value":"2.38","spread":"0.722"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.18","spread":"0.931"},{"groupId":"OG001","value":"2.43","spread":"0.687"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.11","spread":"0.863"},{"groupId":"OG001","value":"2.11","spread":"0.872"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.664"},{"groupId":"OG001","value":"2.27","spread":"0.492"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"0.635"},{"groupId":"OG001","value":"2.34","spread":"0.486"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"0.663"},{"groupId":"OG001","value":"2.32","spread":"0.555"}]}]}]},{"type":"PRIMARY","title":"Conjunctival Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Conjunctival Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of conjunctival redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.66","spread":"0.429"},{"groupId":"OG001","value":"1.98","spread":"0.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.93","spread":"0.388"},{"groupId":"OG001","value":"2.09","spread":"0.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.95","spread":"0.484"},{"groupId":"OG001","value":"2.09","spread":"0.458"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Duration of Action (8 Hours + 30 Minutes)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.84","spread":"0.647"},{"groupId":"OG001","value":"2.19","spread":"0.533"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.18","spread":"0.686"},{"groupId":"OG001","value":"2.33","spread":"0.501"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.21","spread":"0.680"},{"groupId":"OG001","value":"2.30","spread":"0.531"}]}]}]},{"type":"SECONDARY","title":"Ciliary Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ciliary Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of ciliary redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.57","spread":"0.481"},{"groupId":"OG001","value":"1.98","spread":"0.425"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.86","spread":"0.505"},{"groupId":"OG001","value":"2.06","spread":"0.419"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.90","spread":"0.500"},{"groupId":"OG001","value":"2.05","spread":"0.430"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.97","spread":"0.645"},{"groupId":"OG001","value":"2.31","spread":"0.453"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.28","spread":"0.596"},{"groupId":"OG001","value":"2.35","spread":"0.434"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.30","spread":"0.627"},{"groupId":"OG001","value":"2.35","spread":"0.525"}]}]}]},{"type":"SECONDARY","title":"Episcleral Redness at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Episcleral Redness was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of episcleral redness score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.77","spread":"0.460"},{"groupId":"OG001","value":"2.03","spread":"0.461"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.03","spread":"0.461"},{"groupId":"OG001","value":"2.13","spread":"0.448"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.02","spread":"0.488"},{"groupId":"OG001","value":"2.11","spread":"0.477"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.89","spread":"0.557"},{"groupId":"OG001","value":"1.24","spread":"0.635"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.29","spread":"0.656"},{"groupId":"OG001","value":"1.44","spread":"0.747"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.32","spread":"0.718"},{"groupId":"OG001","value":"1.51","spread":"0.803"}]}]}]},{"type":"SECONDARY","title":"Chemosis at Onset of Action (15 Minutes)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Chemosis was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of chemosis score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"0.379"},{"groupId":"OG001","value":"1.03","spread":"0.398"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.99","spread":"0.403"},{"groupId":"OG001","value":"1.28","spread":"0.611"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.14","spread":"0.525"},{"groupId":"OG001","value":"1.43","spread":"0.705"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.68"},{"groupId":"OG001","value":"1.1","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.86"},{"groupId":"OG001","value":"1.2","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.80"},{"groupId":"OG001","value":"1.1","spread":"0.86"}]}]}]},{"type":"SECONDARY","title":"Eyelid Swelling at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Eyelid swelling was assessed by the patient on a 0-3 scale (0=none to 3=severe). Average of eyelid swelling score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.67"},{"groupId":"OG001","value":"1.0","spread":"0.72"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.74"},{"groupId":"OG001","value":"1.0","spread":"0.80"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.77"},{"groupId":"OG001","value":"1.0","spread":"0.89"}]}]}]},{"type":"SECONDARY","title":"Tearing at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.72"},{"groupId":"OG001","value":"1.0","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.92"},{"groupId":"OG001","value":"1.0","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"0.92"},{"groupId":"OG001","value":"0.9","spread":"0.73"}]}]}]},{"type":"SECONDARY","title":"Tearing at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Tearing was assessed by the patient on a 0-4 scale (0=none to 4=severe). Average of tearing score over both eyes was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.67"},{"groupId":"OG001","value":"1.0","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.85"},{"groupId":"OG001","value":"0.9","spread":"0.68"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.84"},{"groupId":"OG001","value":"0.8","spread":"0.67"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.68"},{"groupId":"OG001","value":"1.3","spread":"1.03"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"0.98"},{"groupId":"OG001","value":"1.6","spread":"0.95"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.95"},{"groupId":"OG001","value":"1.5","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Rhinorrhea at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Rhinorrhea was assessed by the patient on a 0-4 scale (0=none to 4=severe). Rhinorrhea score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.77"},{"groupId":"OG001","value":"1.1","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"0.94"},{"groupId":"OG001","value":"1.3","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.01"},{"groupId":"OG001","value":"1.2","spread":"0.87"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritus at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.58"},{"groupId":"OG001","value":"0.8","spread":"0.87"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.82"},{"groupId":"OG001","value":"1.0","spread":"1.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.79"},{"groupId":"OG001","value":"0.9","spread":"0.93"}]}]}]},{"type":"SECONDARY","title":"Nasal Pruritus at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Pruritus was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.4","spread":"0.76"},{"groupId":"OG001","value":"0.6","spread":"0.79"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.97"},{"groupId":"OG001","value":"0.8","spread":"0.91"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":"0.79"},{"groupId":"OG001","value":"0.7","spread":"0.77"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritus at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.5","spread":"0.82"},{"groupId":"OG001","value":"0.8","spread":"1.09"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.11"},{"groupId":"OG001","value":"1.3","spread":"1.16"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.09"},{"groupId":"OG001","value":"1.3","spread":"1.25"}]}]}]},{"type":"SECONDARY","title":"Ear or Palate Pruritus at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Ear or Palate Pruritus was assessed by the patient on a single 0-4 scale (0=none to 4=severe). Ear or Palate Pruritus score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.3","spread":"0.77"},{"groupId":"OG001","value":"0.8","spread":"1.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.98"},{"groupId":"OG001","value":"1.1","spread":"1.14"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.10"},{"groupId":"OG001","value":"1.1","spread":"1.13"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":"0.85"},{"groupId":"OG001","value":"1.2","spread":"1.02"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"1.03"},{"groupId":"OG001","value":"1.6","spread":"0.99"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.0","spread":"1.06"},{"groupId":"OG001","value":"1.5","spread":"1.03"}]}]}]},{"type":"SECONDARY","title":"Nasal Congestion at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. Nasal Congestion was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Congestion score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8","spread":"1.03"},{"groupId":"OG001","value":"1.1","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.16"},{"groupId":"OG001","value":"1.3","spread":"0.90"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","spread":"1.09"},{"groupId":"OG001","value":"1.4","spread":"0.99"}]}]}]},{"type":"SECONDARY","title":"Nasal Composite Score at Duration of Action (8 Hours + 30 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 8 hours + 30 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"82","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"83.7","spread":null},{"groupId":"OG001","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Nasal Composite Score at Onset of Action (15 Minutes Post-dose)","description":"A treatment efficacy CAC was performed 15 minutes after drop instillation. For Nasal Composite Score the Total Composite Score ranges from 0 to 16, higher scores represent greater severity. Patients needed to have at least one of the nasal symptoms present (Rhinorrhea + Nasal Pruritus + Ear or Palate Pruritus + Nasal Congestion) each symptom was assessed by the patient on a 0-4 scale (0=none to 4=severe). Nasal Composite score for each time point was analyzed.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"65.3","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.6","spread":null},{"groupId":"OG001","value":"91.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"77.6","spread":null},{"groupId":"OG001","value":"93.6","spread":null}]}]}]},{"type":"SECONDARY","title":"Tolerability of Study Medication at Visit 3A","description":"Tolerability was assessed upon instillation of study medication, at 1 minute and 2 minutes post study medication instillation. Drop comfort was assessed using a 0-to 10 scale where 0=very comfortable and 10=very uncomfortable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2","spread":"1.42"},{"groupId":"OG001","value":"1.0","spread":"1.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":"1.44"},{"groupId":"OG001","value":"1.2","spread":"1.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"1.44"},{"groupId":"OG001","value":"1.0","spread":"1.50"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":50},"commonTop":["Visual Acuity Reduced","Eye Pain","Punctate Keratitis","Lower Respiratory Tract Infection","Sinusitis"]}}}